{"schema_version":"secwatch.filing_event.v1","accession":"0001860742-26-000086","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2026-07-29T11:02:15+00:00","discovered_at":"2026-07-29T11:05:00.286772+00:00","generated_at":"2026-07-29T11:05:10.061408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bausch + Lomb Q2 revenue $1.394B (+9% YoY); raises FY2026 guidance","bullets":["Revenue $1.394B, up 9% reported and 8% constant currency YoY; GAAP net loss $14M vs $62M loss.","Adjusted EBITDA $241M (+$50M YoY); Adjusted EBITDA ex-IPR&D $246M.","Surgical revenue +19% (premium IOLs up 175%); Pharmaceuticals +15% (MIEBO/XIIDRA +27% H1).","FY2026 revenue guidance raised to $5.44B-$5.54B; Adj. EBITDA ex-IPR&D raised to $1.025B-$1.075B.","Cash flow from operations $153M, up from $35M; GAAP EPS ($0.04), adjusted EPS $0.15."],"urls":{"canonical":"https://secwatch.observer/filing/0001860742-26-000086","json":"https://secwatch.observer/filing/0001860742-26-000086.json","markdown":"https://secwatch.observer/filing/0001860742-26-000086.md","text":"https://secwatch.observer/filing/0001860742-26-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000086/0001860742-26-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000086/blco-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:05:10.061408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}